Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

PURPOSE: Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metastatic cervical, vaginal, or vulvar cancers. PATIENTS AND METHODS: Patients received nivolumab 240 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Naumann, R. Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M., Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R.J., Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L., Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823884/
https://www.ncbi.nlm.nih.gov/pubmed/31487218
http://dx.doi.org/10.1200/JCO.19.00739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823884/
https://www.ncbi.nlm.nih.gov/pubmed/31487218
http://dx.doi.org/10.1200/JCO.19.00739

Ejemplares similares